JUNE 4, 2022, NEW YORK – A Ludwig Cancer Research study has demonstrated that circulating tumor DNA (ctDNA) which is shed from tumors into the bloodstream can identify stage II colon cancer patients most likely to benefit from chemotherapy and help others avoid unnecessary treatment.
Ludwig Johns Hopkins study establishes utility of circulating tumor DNA for post-surgical management of stage II colon cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Date Time
Ludwig Johns Hopkins researchers develop new DNA detection method to improve liquid biopsies
May 6, 2021, NEW YORK – A team of researchers at the Ludwig Center at Johns Hopkins has developed a far more sensitive and accurate next-generation gene sequencing technology for the detection of rare fragments of mutated DNA shed by tumors into body fluids.
The detection of such DNA fragments-commonly referred to as “liquid biopsies”-holds the promise of easing the detection of cancers at their earliest stages, when they are most likely to be curable.
In a study led by Ludwig Johns Hopkins researchers Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos and MD-PhD student Joshua Cohen and published May 3 in Nature Biotechnology, the team reported the development and analytical assessment of SaferSeqS (for “Safer Sequencing System”). Their report shows that SaferSeqS is a major improvement over a now widely adopted method developed at Ludwig Johns Hopkins a decade a